VisEn Medical, Inc.

VisEn Launches Next-Generation FAST (“Fluorescence Activatible Sensor Technology”) Agent Platform for Expanded Performance in Imaging Disease Biomarkers In Vivo

VisEn Launches Next-Generation FAST (“Fluorescence Activatible Sensor Technology”) Agent Platform for Expanded Performance in Imaging Disease Biomarkers In Vivo

April 20, 2009

MMPSense™ 750 FAST is Presented at AACR 100th Annual Meeting

Acceleron Pharma, Inc.

Acceleron Announces Expansion of Cambridge Facilities by Additional 25% During Formal Unveiling of New Corporate Headquarters and Manufacturing Facility

Acceleron Announces Expansion of Cambridge Facilities by Additional 25% During Formal Unveiling of New Corporate Headquarters and Manufacturing Facility

May 1, 2009

Lt. Governor Murray and other Massachusetts Dignitaries on Hand to Celebrate Rapid Growth of Acceleron Product Pipeline and Plans to Further Increase Workforce

Pervasis Therapeutics, Inc.

Pervasis Therapeutics Granted Orphan Drug Designation for Vascugel®

Pervasis Therapeutics Granted Orphan Drug Designation for Vascugel®

May 5, 2009

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Pervasis Therapeutics, Inc., a biotechnology company pioneering biologically active cellular therapies to treat vascular and other serious diseases, today announced that it has received Orphan Drug Designation for Vascugel®, a novel allogeneic cell therapy product that may restore natural repair and regeneration pathways in the vasculature, from the U.S. Food and Drug Administration (FDA).

Resolvyx Pharmaceuticals, Inc.

Resolvyx Presents Data Demonstrating Potential for Resolvin Therapeutics to Treat Corneal and Retinal Eye Diseases at ARVO 2009 Meeting

Resolvyx Presents Data Demonstrating Potential for Resolvin Therapeutics to Treat Corneal and Retinal Eye Diseases at ARVO 2009 Meeting

May 7, 2009

RX-10045 Promotes Corneal Epithelial Repair in Model System

Topical Administration of Resolvin Effective in Model of Wet AMD

Helicos BioSciences Corporation

Helicos Demonstrates The Utility of Its Single Molecule Sequencing Platform at Cold Spring Harbor Genome Conference

Helicos Demonstrates The Utility of Its Single Molecule Sequencing Platform at Cold Spring Harbor Genome Conference

May 8, 2009

The Helicos System Produces Better Scientific Results with Less Sequencing Required

Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals Granted Patents on Deuterium-Modified Compounds

Concert Pharmaceuticals Granted Patents on Deuterium-Modified Compounds

May 11, 2009

LEXINGTON, Mass -- Concert Pharmaceuticals, Inc. announced today that its first patents have been granted by the U.S. Patent and Trademark Office. These patents relate to specific compounds derived from Concert’s deuterium chemistry platform. U.S. Patents 7,514,068 and 7,528,131 specifically claim deuterium analogs of rimonabant and mosapride, respectively. In addition to these patents, Concert has over 100 pending U.S. patent applications and corresponding applications worldwide.

AVEO Pharmaceuticals, Inc.

AVEO Pharmaceuticals’ Scientific Advisory Board Members Recognized for Contributions to Cancer Research and Medicine

AVEO Pharmaceuticals’ Scientific Advisory Board Members Recognized for Contributions to Cancer Research and Medicine

May 13, 2009

SAB Members Elected to NAS and IOM; Honored with Awards from AACR and NFCR

Helicos BioSciences Corporation

Helicos BioSciences Reports Q1 2009 Financial Results

Helicos BioSciences Reports Q1 2009 Financial Results

May 14, 2009

Achieves First Instrument Revenue and Significant Milestones

CAMBRIDGE, Mass., May 14, 2009 -- Helicos BioSciences Corporation (NASDAQ: HLCS) announced today its financial results for the quarter ended March 31, 2009.

LS9

LS9 and Procter & Gamble Launch Sustainable Chemicals Partnership

LS9 and Procter & Gamble Launch Sustainable Chemicals Partnership

May 19, 2009

Confirms P&G’s Commitment to Sustainable Innovation

Accelerates LS9’s Entry into the Consumer Product Chemicals Market

Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals Appoints David Schenkein, M.D. as CEO and Duncan Higgons as COO

Agios Pharmaceuticals Appoints David Schenkein, M.D. as CEO and Duncan Higgons as COO

May 27, 2009

Industry Leaders Bring Deep Oncology and Company Building Experience